#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Self-administration of alpha-1-antitrypsin can significantly improve patients' quality of life

Treatment of alpha-1 antitrypsin deficiency (AATD) requires lifetime administration of weekly intravenous infusions of this substance, mostly in medical facilities. The possibility of AAT application at home is being discussed. This topic was also addressed at a symposium held during the European Respiratory Society (ERS) congress, which took place in November 2019 in Madrid.
Source: Deficiency of Alpha-1-Antitrypsin 20. 8. 2020

News Experience from Clinical Practice with Intestinal Gel LECIG in Treating Parkinson's Disease

A Swedish observational study evaluated the applicability of the LECIG intestinal gel, which contains levodopa (20 mg/ml), carbidopa (5 mg/ml), and entacapone (20 mg/ml), in clinical practice for patients with Parkinson's disease.
Source: Parkinson's Disease 12. 5. 2022

News ESC 2022: How to use gliflozins in heart failure? American guidelines now also consider the EMPEROR-Preserved study

One of the important current cardiology topics is the possibility of using gliflozins in patients with chronic heart failure (HF) regardless of the left ventricular ejection fraction (LVEF). The possibilities of introducing these medicines into clinical practice, considering the issue in international guidelines, and the results of empagliflozin in recent studies were covered in a practically oriented symposium as part of the professional program of this year's European Society of Cardiology Congress (ESC 2022).
Source: Heart Failure 13. 10. 2022

News Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment

Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.
Source: Cough Therapy 24. 5. 2022

News Recurring allergy symptoms after waking up? It could be due to dust mites

Allergens that are part of the feces and exoskeleton of dust mites, invisible members of human households, can cause milder symptoms like mucosal swelling, itching of the nose or throat, but also a stronger immune reaction, asthma, or severe allergic rhinitis. It is stated that 1−2% of the global population suffers from dust mite allergy, which corresponds to 65−130 million people. Why does it arise and what can be done in its prevention and treatment?
Source: Dust Mite Allergy 19. 1. 2022

News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis – Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.
Source: Arthritis 30. 5. 2022

News Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis – Real-World Clinical Practice Data

The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published review summarizing retrospective, prospective, and observational studies from real-world clinical practice published in 2018–2020, the treatment duration with tofacitinib is comparable to that with biological disease-modifying drugs.
Source: Arthritis 29. 3. 2022

News Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene

PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
Source: Colorectal Cancer 14. 10. 2023

News Heart Failure in the Light of New ESC Guidelines

Dear Doctor, The Czech Society of Internal Medicine of ČLS JEP invites you to watch the symposium, which will take place on Wednesday, November 3rd, at 5 PM.
You can find more information in the invitation attached below.
Source: Heart Failure 27. 10. 2021

News Is it possible to predict survival time based on laboratory or radiological findings in patients with IPF?

High-resolution computed tomography (HRCT) imaging of the lungs is a fundamental examination in diagnosing idiopathic pulmonary fibrosis (IPF). According to experts from the Mayo Clinic, it can also serve as a tool for more accurate prediction of survival time in IPF patients.
Source: Pulmonary Fibrosis 26. 11. 2020

News Patient with Moderate Hemophilia A and Development of FVIII Inhibitor in Old Age and Atrial Fibrillation − Interactive Case Study

MUDr. Petr Smejkal, Ph.D., from the Department of Clinical Hematology, FN Brno, has prepared a case study for you of a patient born in 1941, diagnosed with hemophilia A at around 10 years of age. In 2013, he underwent surgery for right carotid stenosis with pdFVIII substitution and was started on acetylsalicylic acid. Two weeks after discharge, subcutaneous and muscle bleeding was recognized, leading to the development of an FVIII inhibitor (high responder) with FVIII levels < 1%. Severe muscle bleeds continued approximately once every 2 months. Prophylactic treatments progressively included aPCC, pdFVIII, and emicizumab. The patient also presents with cardiovascular comorbidities: atrial fibrillation (AF) accompanied by its dilatation, diastolic heart failure, and hypertension. In 2021, he also contracted COVID-19, requiring hospitalization.
Source: Quality Life Even with Hemophilia 22. 9. 2021

News Boy with Hemophilia A with Inhibitor − Case Study with Voting

Presented by: Assoc. Prof. MUDr. Jan Blatný, Ph.D., Department of Pediatric Hematology, University Hospital Brno
Source: Quality Life Even with Hemophilia 22. 4. 2020

News Bimekizumab in the Treatment of Psoriasis After Failure of (Not Only) Anti-IL-17A Antibodies – Case Reports

German authors last year described the first 2 cases of patients with psoriasis in whom treatment with, among other things, anti-IL-17A antibodies failed, but who responded to the blockade of interleukins IL-17A/IL-17F with bimekizumab after its approval by the European Medicines Agency (EMA).
Source: Psoriasis 2. 4. 2023

News Primum non nocere applies not only in medicine: an ecological look at inhalers

According to estimates from the World Health Organization (WHO), around 65 million people worldwide suffer from mild to moderate forms of chronic obstructive pulmonary disease (COPD). The cornerstone of therapy is the inhalation administration of bronchodilator drugs. While there is no doubt that this therapy helps patients, what impact do the propellants in inhalation systems have on the global climate? And is there a sensible solution to this problem?
Source: COPD 25. 5. 2020

News INFOGRAPHIC: Which treatment to choose in the 1st line for a patient with type 2 diabetes?

Diabetes mellitus is a complex chronic disease that requires continuous treatment and a strategy to reduce associated risks beyond mere glycemic control. Comorbidities and the risk of complications are key elements in deciding the choice of therapy for type 2 diabetics. This fact is also considered by the American Diabetes Association (ADA) in its annually published standards of care for patients with diabetes, which brought several changes in 2022.
Source: Diabetes 24. 2. 2023

News INFOGRAPHIC: Diagnosis and Monitoring of Patients with Hypertrophic Cardiomyopathy – Current Guidelines

What examinations should be conducted when suspecting hypertrophic cardiomyopathy, a hereditary disease caused by mutations in genes encoding cardiac muscle proteins? What is the subsequent procedure for monitoring patients and their at-risk relatives? The comprehensive infographic summarizes the current recommendations of American professional societies.
Source: Hypertrophic Cardiomyopathy (HCM) 1. 11. 2023

News Case Study with Voting: Intensification of Type 2 Diabetes Therapy in a Chronically Treated Patient. How to Proceed According to Current Recommendations?

We have prepared an interactive case study for you with a 70-year-old patient with decompensated Type 2 Diabetes. The patient was diagnosed with DM eight years ago. What treatment approach would you choose? And why? And how should you correctly proceed according to the current recommendations of SVL? Watch a short video with us.
Source: Diabetes 12. 11. 2020

News High pH of Wounds is Associated with Poorer Burn Healing

British scientists have shown that the pH of burn wounds decreases during healing and that higher pH at the second dressing change is associated with poorer healing and the subsequent need for skin grafts. Determining the pH of wounds at the beginning of treatment could help identify poorly healing burns that require more aggressive treatment.
Source: Wound Healing 24. 2. 2020

News Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin

Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.
Source: Heart Failure 14. 1. 2022

News Improvement of Executive Functions in Therapy of Dravet Syndrome with Fenfluramine in Preschool Children

Dravet syndrome is a rare genetic progressive epileptic encephalopathy that is usually accompanied by intellectual and behavioral disorders. Many children with this syndrome also struggle with deficits in executive functions. An analysis recently published in the journal Epilepsy & Behavior assessed the impact of fenfluramine therapy on executive functions in preschool children with this condition.
Source: Rare Diseases in Neurology 10. 10. 2023

News Options for Modifying and Improving the Efficiency of the HJHS Scoring System

The Hemophilia Joint Health Score (HJHS) is a validated tool for assessing joint health in individuals with hemophilia. Can it be modified to be used more effectively in clinical practice?
Source: Hemophilia with Movement 30. 11. 2020

News Position of Levodropropizine in Cough Therapy

An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using Medline and Embase databases, and they presented their work's results last year in the journal Pulmonary Pharmacology & Therapeutics.
Source: Cough Therapy 15. 1. 2020

News Does the Risk of Recurrence of Differentiated Thyroid Carcinoma Differ by Gender?

Differentiated thyroid carcinomas (DTC) are typically diagnosed at more advanced stages in men than in women, and mortality from this disease is higher among men than women. However, it was not entirely clear whether the risk of DTC recurrence is influenced by the patient's gender independently of the disease stage at the time of diagnosis. The aim of the Canadian authors' study was to assess whether male gender is an independent risk factor for DTC recurrence.
Source: Thyroid Disorders 14. 2. 2020

News Immunotolerance is still the goal of management of hemophilia A with inhibitor in the era of non-factor therapy

New molecules in hemophilia therapy have raised many questions, including regarding the significance and need for immune tolerance induction (ITI). Interesting conclusions from the FIT (Future of Immunotolerance Treatment) expert panel discussion on the future of ITI, its form, and indication were published in July 2019.
Source: Hemophilia 18. 3. 2020

News Alpha-1-Antitrypsin Deficiency and Its Association with Atopy in Asthmatics

Literature mentions the coincidence of asthma and alpha-1-antitrypsin deficiency, which is caused by a mutation in the SERPINA1 gene. The aim of the study presented below was to determine whether the clinical symptoms of asthma differ between patients with and without this mutation.
Source: Deficiency of Alpha-1-Antitrypsin 14. 5. 2021

1 17 18 19 20 21 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#